2 Stocks Down 8% or More That Are Screaming Buys Right Now

Intuitive Surgical’s da Vinci 5 rollout is driving an improving base: Q2 sales totaled 468 systems, including 246 da Vinci 5 units, lifting the installed base to 11,710 (+12% YoY), even as the stock remains down 34% YTD on lower near-term margins. Novo Nordisk, down 8% YTD after losing GLP-1 leadership, is betting on renewed momentum from candidates amycretin (up to 24.3% weight loss in 36 weeks) and UBT251 (up to 19.7% in 24 weeks in phase 2 China), alongside progress with its oral Wegovy pill. Overall, the article frames both names as long-term recovery stories despite recent setbacks.

Analysis

Intuitive Surgical looks less like a product-cycle story and more like a monetization story: the near-term margin optics on the new platform matter less than whether it pulls forward console placements that later convert into higher-margin consumable pull-through. If procedure mix continues to rise, the installed base can re-rate the stock over 6-18 months even if reported hardware gross margins stay under pressure for a few quarters. The first-order winner is ISRG; the second-order losers are competing robotic programs that still need proof of economic payback, especially where hospitals are scrutinizing utilization math.

Novo Nordisk’s real issue is not whether the science works, but whether the company can defend access, pricing, and share while the category expands. Next-gen incretins create optionality, yet the market will likely demand evidence that these assets convert into payer-backed volume rather than just headline efficacy; that makes the next 1-3 clinical/regulatory milestones more important than the current pipeline narrative. If oral adoption scales, it is a negative for cash-pay weight-loss clinics and telehealth intermediaries that thrive on friction, but the bigger swing factor remains whether Eli Lilly forces a permanent multiple discount.

The consensus may be underestimating how path-dependent both names are: ISRG needs utilization to outrun hardware dilution, while NVO needs a credible bridge from promise to reimbursement. In both cases, the current weakness can be either a durable entry point or a value trap depending on next-quarter operating metrics, not long-dated storylines. The clearest falsifiers are flat-to-down procedure growth for ISRG and any sign that NVO’s next readout/regulatory cadence fails to narrow the gap versus LLY.

Key Decisions for Investors

• Stagger into a 6-12 month long ISRG only on additional post-earnings weakness; thesis breaks if procedure growth decelerates or the new-system mix fails to lift consumable pull-through.
• Use NVO as a 12-24 month catalyst-driven long, ideally via call spreads rather than outright equity, ahead of next obesity pipeline inflection points; cut if payer/access commentary implies ongoing share loss to LLY.
• Relative-value idea: long ISRG / short MDT as a robotics adoption pair for 1-2 quarters, betting scale and installed-base economics matter more than newer-platform marketing; stop if MDT booking trends accelerate or ISRG margins do not stabilize.
• If needing a cleaner GLP-1 exposure, prefer NVO over chasing LLY here on a valuation basis, but only with a defined risk limit until clinical and reimbursement data confirm the turnaround.